Groundbreaking journal AI in Precision Oncology publishes preview content

The fusion of artificial intelligence (AI)-enabled technologies and precision oncology is advancing at an unprecedented pace, and the introduction of the new peer-reviewed journal, AI in Precision Oncology, will support clinicians, researchers, AI experts, patients, and industry leaders with up-to-date advancements in the field while fostering an environment conducive to further innovation and collaboration. A preview issue of the journal is now available. Click here to read the issue now. 

“At the heart of my vision for this journal is the unwavering belief that AI can help make care more human,” Editor-in-Chief Douglas Flora, MD, writes in his opening Editorial. “AI in Precision Oncology is more than just a scientific or medical journal; it is a mission-driven initiative to harness the power of AI in improving oncology care. In the process, we aim to shape an AI-enabled health care system that is equitable, efficient, and patient centered—making health care more human.”

The preview issue includes an interview with Dr. Flora, conducted by Damian Doherty, Editor-in-Chief of Inside Precision Medicine. In the interview, Dr. Flora, who is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare in northern Kentucky, discusses his clinical and leadership roles and his conviction that AI will revolutionize the practice of oncology.

In the Commentary titled “’We’re Doing it Wrong!’ Phenomics and Hyperscale AI for Health Care,” Leroy Hood, MD, PhD, from the Institute for Systems Biology, and Scott Penberthy, PhD, from Google Cloud, contend that phenomics is the game changer. “Phenomics takes everything we know about your body—your genes, quantification of the proteins and metabolites in your blood, the tiny microbes living in your gut, even the heart rate and distance data from your smartwatch—and blends its data together to create a predictive picture of you.”

Scott Penberthy, PhD, authored a Commentary titled “What is Artificial Intelligence? An Insight for Oncologists.” This is the first in what will be a series of articles describing AI, its capabilities, and its applications in oncology.

“Prompt Assistance” will be a regular column in AI in Precision Oncology dedicated to highlighting and recommending specific applications of AI tools such as ChatGPT in clinical practices. In this issue, Dr. Flora and Nikhil Thaker, from Capital Health Radiation Oncology, contributed the article titled “Designing Prompts for Generative Artificial Intelligence in Clinical Oncology Contexts.” They present ten key guidelines to assist users get the best out of their AI queries.

In the Commentary titled “Realizing the Promise of Tumor Infiltrating Lymphocytes as a New Biomarker for Personalized Medicine May Require the Power and Precision of Artificial Intelligence,” Michael Montalto, from PathAI, discusses the use of AI algorithms to analyze large datasets of histological stains and quantify the density and distribution of immune cells within the tumor microenvironment.

An original research article titled “AI-Augmented Clinical Decision Support in a Patient-Centric Precision Oncology Registry” was contributed by Mark Shapiro, from xCures, Inc. and coauthors. The authors describe xDECIDE, a clinical decision support system that is accessed through a web portal and powered by a “Human-AI Team,” which offers oncology healthcare providers with treatment options personalized for their cancer patients and outcomes tracking.

Pranali Pachika, MD, from the University of Louisville, and coauthors, contributed the Review article titled “The Use of Artificial Intelligence in Lung Cancer Management.” Treatment for lung cancer is highly individualized. The authors describe how artificial intelligence components such as machine learning and deep learning can be applied in all stages of lung cancer, including screening, diagnosis, therapy selection, prognosis, and surveillance.

To request a print copy of the preview issue, click here.

About the Journal
AI in Precision Oncology is the only peer-reviewed journal dedicated to the advancement of artificial intelligence applications in clinical and precision oncology. Spearheaded by Editor-in-Chief Douglas Flora, MD and supported by a diverse and accomplished team of international experts, the Journal provides a high-profile forum for cutting-edge research and frontmatter highlighting important research and industry-related advances rapidly developing within the field. For complete information, visit the AI in Precision Oncology website.

About the Publisher
Mary Ann Liebert, Inc. is a global media company dedicated to creating, curating, and delivering impactful peer-reviewed research and authoritative content services to advance the fields of biotechnology and the life sciences, specialized clinical medicine, and public health and policy. For complete information, please visit the Mary Ann Liebert, Inc. website.